187 related articles for article (PubMed ID: 19643487)
1. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
Cursiefen C; Bock F; Horn FK; Kruse FE; Seitz B; Borderie V; Früh B; Thiel MA; Wilhelm F; Geudelin B; Descohand I; Steuhl KP; Hahn A; Meller D
Ophthalmology; 2009 Sep; 116(9):1630-7. PubMed ID: 19643487
[TBL] [Abstract][Full Text] [Related]
2. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
Cursiefen C; Viaud E; Bock F; Geudelin B; Ferry A; Kadlecová P; Lévy M; Al Mahmood S; Colin S; Thorin E; Majo F; Frueh B; Wilhelm F; Meyer-Ter-Vehn T; Geerling G; Böhringer D; Reinhard T; Meller D; Pleyer U; Bachmann B; Seitz B
Ophthalmology; 2014 Sep; 121(9):1683-92. PubMed ID: 24811963
[TBL] [Abstract][Full Text] [Related]
3. Drops for corneal neovascularization.
Das M; Murthy S
Ophthalmology; 2010 Oct; 117(10):2042; author reply 2042-3. PubMed ID: 20888488
[No Abstract] [Full Text] [Related]
4. Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.
Kain H; Goldblum D; Geudelin B; Thorin E; Beglinger C
Br J Clin Pharmacol; 2009 Aug; 68(2):169-73. PubMed ID: 19694734
[TBL] [Abstract][Full Text] [Related]
5. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
6. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
7. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.
Petsoglou C; Balaggan KS; Dart JK; Bunce C; Xing W; Ali RR; Tuft SJ
Br J Ophthalmol; 2013 Jan; 97(1):28-32. PubMed ID: 23087419
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial.
Shimazaki J; Iseda A; Satake Y; Shimazaki-Den S
Ophthalmology; 2012 Apr; 119(4):668-73. PubMed ID: 22264885
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Trinquand C; Romanet JP; Nordmann JP; Allaire C;
J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
[TBL] [Abstract][Full Text] [Related]
10. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
[TBL] [Abstract][Full Text] [Related]
11. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
[TBL] [Abstract][Full Text] [Related]
14. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
15. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1.
Al-Mahmood S; Colin S; Farhat N; Thorin E; Steverlynck C; Chemtob S
J Pharmacol Exp Ther; 2009 May; 329(2):496-504. PubMed ID: 19208899
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Zhang Z; Ma JX; Gao G; Li C; Luo L; Zhang M; Yang W; Jiang A; Kuang W; Xu L; Chen J; Liu Z
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
[TBL] [Abstract][Full Text] [Related]
17. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
[TBL] [Abstract][Full Text] [Related]
18. Visual acuity and intraocular pressure after Descemet's stripping endothelial keratoplasty in eyes with and without preexisting glaucoma.
Vajaranant TS; Price MO; Price FW; Gao W; Wilensky JT; Edward DP
Ophthalmology; 2009 Sep; 116(9):1644-50. PubMed ID: 19643499
[TBL] [Abstract][Full Text] [Related]
19. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.
Ogawa Y; Okamoto S; Mori T; Yamada M; Mashima Y; Watanabe R; Kuwana M; Tsubota K; Ikeda Y; Oguchi Y
Bone Marrow Transplant; 2003 Apr; 31(7):579-83. PubMed ID: 12692625
[TBL] [Abstract][Full Text] [Related]
20. High-dose topical bevacizumab for corneal neovascularization.
Waisbourd M; Levinger E; Varssano D; Moisseiev E; Zayit-Soudri S; Barak A; Loewenstein A; Barequet I
Pharmacology; 2013; 92(5-6):310-4. PubMed ID: 24335191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
